Research Article
Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
Table 5
Changes over time in specific parameters related to the quality of life in esophageal cancer. QLQ-OES-18 questionnaire.
| | QLQ-OES-18 domain | Baseline (N = 87) | Treatment maintenance | Value | | Month 3 (N = 27) | Month 6 (N = 17) | Month 12 (N = 15) | | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| | Dysphagia | 39.5 (22.6) | 58.0 (23.5) | 53.6 (28.4) | 52.6 (31.6) | 0.02 | | Eating difficulties | 42.0 (25.9) | 27.2 (27.8) | 28.4 (28.1) | 19.4 (23.9) | 0.0001 | | Reflux | 23.9 (26.4) | 25.6 (25.0) | 28.4 (21.9) | 18.9 (22.6) | 0.39 | | Esophageal pain | 26.3 (25.4) | 22.6 (26.9) | 20.9 (27.2) | 17.0 (25.5) | 0.24 | | Trouble swallowing saliva | 25.2 (27.5) | 19.8 (29.6) | 15.7 (20.8) | 15.6 (24.8) | 0.06 | | Choking when swallowing | 46.0 (31.4) | 22.2 (27.7) | 37.3 (35.1) | 22.2 (30.0) | 0.0006 | | Dry mouth | 23.0 (29.8) | 9.9 (18.1) | 17.6 (26.7) | 20.0 (21.1) | 0.66 | | Trouble with taste | 15.7 (28.7) | 17.3 (31.2) | 7.8 (18.7) | 6.7 (13.8) | 0.49 | | Trouble with coughing | 21.5 (27.4) | 16.0 (29.8) | 13.7 (23.7) | 4.4 (11.7) | 0.48 | | Speech difficulties | 12.6 (26.0) | 4.9 (12.1) | 9.8 (15.7) | 6.7 (13.8) | 0.21 |
|
|
Statistically significant values according to the ANOVA test for repeated measurements. SD: standard deviation. |
